FTC: Number of Pay-for Delay Settlements Continues to Drop

Generic Line
A A
The number of “pay-for-delay” patent settlements agreed to by pharmaceutical companies in fiscal 2015 declined from the year before, according to a report from the Federal Trade Commission.

To View This Article:

Login

Subscribe To Generic Line